FDA Orange Book
Generic for Lumi-sporyn
Lumi-sporyn contains neomycin, polymyxin b and bacitracin zinc. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Lumi-sporyn is neomycin, polymyxin b and bacitracin zinc. 1 company holds an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AT.
Run it in Rivvi
Map Lumi-sporyn and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Lumi-sporyn products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| ointment, ophthalmic | 400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM | Marketed (Rx) | AT | 1 | AT |
NDA 050417, held by CASPER PHARMA LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic neomycin, polymyxin b and bacitracin zinc
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| BAUSCH AND LOMB INC | 064064 | AT (A-rated, therapeutically equivalent) | October 30, 1995 | 400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM |
Questions
Is there a generic for Lumi-sporyn?
Yes. The generic name for Lumi-sporyn is neomycin, polymyxin b and bacitracin zinc. 1 company holds an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AT.
What is the generic name for Lumi-sporyn?
The active ingredient in Lumi-sporyn is neomycin, polymyxin b and bacitracin zinc, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.